Press Releases

Legislation will help spur the development of lifesaving treatments and cures WASHINGTON D.C. (February 25, 2025) – John Crowley, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement…

Urges Congress to support rare disease patients & support the billWASHINGTON, D.C. (February 5, 2025) – John F. Crowley, President & CEO of the Biotechnology Innovation Organization (BIO), today released the following statement after…

WASHINGTON, D.C. (January 17, 2025) – The Biotechnology Innovation Organization (BIO) today released the following statement after the Biden administration released a list of 15 medicines being selected for government price setting:“In the final…

Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) corn. In response, John Crowley, President…

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a year-end government funding bill that includes many…

Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications veteran, will join BIO’s senior leadership team. Her first day will be…

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic performance, its impacts, and its geographic…

BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…

“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…